This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

9JV0 Stock Overview

Engages in the development of ophthalmic drugs for medical needs in Sweden. More details

9JV0 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Earnings have grown 1.1% per year over the past 5 years

Risk Analysis

Makes less than USD$1m in revenue (SEK0)

Has less than 1 year of cash runway

Shareholders have been substantially diluted in the past year

Does not have a meaningful market cap (€3M)

+ 1 more risk

My Notes

Capture your thoughts, links and company narrative

Redwood Pharma AB Competitors

Biofrontera

XTRA:B8FK

€15.5m

SynBiotic

DUSE:SBX

€27.7m

Cantourage Group

XTRA:HIGH

€56.9m

Redx Pharma

DB:0RX

€65.0m

Price History & Performance

Summary of share price highs, lows and changes for Redwood Pharma
Historical stock prices
Current Share Price	€0.081
52 Week High	€1.04
52 Week Low	€0.057
Beta	0.41
1 Month Change	-3.58%
3 Month Change	9.78%
1 Year Change	-92.23%
3 Year Change	-99.84%
5 Year Change	n/a
Change since IPO	-99.89%

Recent updates

Shareholder Returns

	9JV0	DE Pharmaceuticals	DE Market
7D	0%	1.6%	3.0%
1Y	-92.2%	-14.7%	19.3%

Return vs Industry: 9JV0 underperformed the German Pharmaceuticals industry which returned -14.8% over the past year.

Return vs Market: 9JV0 underperformed the German Market which returned 4.2% over the past year.

Price Volatility

Is 9JV0's price volatile compared to industry and market?
9JV0 volatility
9JV0 Average Weekly Movement	59.4%
Pharmaceuticals Industry Average Movement	4.4%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	11.4%
10% least volatile stocks in DE Market	2.5%

Stable Share Price: 9JV0's share price has been volatile over the past 3 months.

Volatility Over Time: 9JV0's weekly volatility has increased from 40% to 59% over the past year.

About the Company

Founded	Employees	CEO	Website
2012	1	MV Vidaeus	www.redwoodpharma.se

Redwood Pharma AB engages in the development of ophthalmic drugs for medical needs in Sweden. Its lead development product is RP101, an eye drop that treats severe chronic dry eye disease in post-menopausal women; and RP501, a next generation smart hydrogel medical device for the treatment of mild dry eye. The company was founded in 2012 and is headquartered in Stockholm, Sweden.

Redwood Pharma AB Fundamentals Summary

How do Redwood Pharma's earnings and revenue compare to its market cap?
9JV0 fundamental statistics
Market cap	€3.14m
Earnings (TTM)	-€1.18m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.2x

P/E Ratio

Is 9JV0 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
9JV0 income statement (TTM)
Revenue	SEK 0
Cost of Revenue	SEK 0
Gross Profit	SEK 0
Other Expenses	SEK 13.60m
Earnings	-SEK 13.60m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-5.12
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did 9JV0 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/08/18 02:37
End of Day Share Price	2024/07/26 00:00
Earnings	2024/03/31
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Redwood Pharma AB is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Markus Augustsson	Carlsquare AB